Fermenta Biotech Limited has released its unaudited financial results for the second quarter of the fiscal year 2025, highlighting notable revenue growth and fluctuations in profit figures.
Key Financial Highlights for Q2 FY25:
- Revenue from Operations: Fermenta Biotech reported revenue from operations of ₹95.03 crore, showing a strong YoY increase of 67% compared to ₹56.91 crore in Q2 FY24. Sequentially, revenue rose by 21.6% from ₹78.13 crore in Q1 FY25.
- Total Income: Including other income, the total income for Q2 FY25 was ₹97.91 crore, marking a YoY increase of 66.5% from ₹58.81 crore in Q2 FY24 and a QoQ rise of 20.9% from ₹80.95 crore in Q1 FY25.
- Profit/Loss Before Tax: Fermenta reported a profit before tax of ₹11.82 crore in Q2 FY25, a considerable recovery from the loss of ₹21.63 crore in Q2 FY24. This was a sequential improvement from a loss of ₹5.93 crore in Q1 FY25.
- Net Profit/Loss: The company achieved a net profit of ₹11.12 crore for Q2 FY25, recovering from a loss of ₹29.06 crore in the previous year. Sequentially, the net profit improved from a loss of ₹5.93 crore in Q1 FY25.
Analysis and Outlook:
The significant YoY growth in revenue reflects Fermenta Biotech’s progress in operational performance and product demand. However, the company’s profitability remains under pressure due to fluctuating cost structures and expenses. The recovery from losses in previous quarters suggests an improved financial trajectory, though maintaining this momentum will require continued efficiency and effective cost management.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Neither the author nor Business Upturn is liable for any losses arising from the use of this information.
